| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Identification of motifs in the fasciclin domains of the transforming growth factor-beta-induced matrix protein betaig-h3 that interact with the alphavbeta5 integrin.
|
J Biol Chem
|
2002
|
1.53
|
|
2
|
Transforming growth factor-beta-induced protein (TGFBIp/beta ig-h3) activates platelets and promotes thrombogenesis.
|
Blood
|
2009
|
1.42
|
|
3
|
Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy.
|
J Control Release
|
2008
|
1.38
|
|
4
|
Betaig-h3 supports keratinocyte adhesion, migration, and proliferation through alpha3beta1 integrin.
|
Biochem Biophys Res Commun
|
2002
|
1.38
|
|
5
|
Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring.
|
J Control Release
|
2010
|
1.37
|
|
6
|
Self-assembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for doxorubicin: in vivo biodistribution and anti-tumor activity.
|
Biomaterials
|
2006
|
1.32
|
|
7
|
Identification of the alphavbeta3 integrin-interacting motif of betaig-h3 and its anti-angiogenic effect.
|
J Biol Chem
|
2003
|
1.31
|
|
8
|
Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice.
|
J Control Release
|
2007
|
1.29
|
|
9
|
Beta ig-h3 promotes renal proximal tubular epithelial cell adhesion, migration and proliferation through the interaction with alpha3beta1 integrin.
|
Exp Mol Med
|
2004
|
1.23
|
|
10
|
RGD peptides released from beta ig-h3, a TGF-beta-induced cell-adhesive molecule, mediate apoptosis.
|
Oncogene
|
2003
|
1.19
|
|
11
|
Erythropoietin decreases renal fibrosis in mice with ureteral obstruction: role of inhibiting TGF-beta-induced epithelial-to-mesenchymal transition.
|
J Am Soc Nephrol
|
2007
|
1.18
|
|
12
|
Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy.
|
ACS Nano
|
2011
|
1.18
|
|
13
|
Tumor-targeting peptide conjugated pH-responsive micelles as a potential drug carrier for cancer therapy.
|
Bioconjug Chem
|
2010
|
1.16
|
|
14
|
Molecular properties of wild-type and mutant betaIG-H3 proteins.
|
Invest Ophthalmol Vis Sci
|
2002
|
1.14
|
|
15
|
Self-assembled glycol chitosan nanoparticles for the sustained and prolonged delivery of antiangiogenic small peptide drugs in cancer therapy.
|
Biomaterials
|
2008
|
1.12
|
|
16
|
Targeting bladder tumor cells in vivo and in the urine with a peptide identified by phage display.
|
Mol Cancer Res
|
2007
|
1.10
|
|
17
|
Polymorphisms in TGF-beta1 gene and the risk of lung cancer.
|
Lung Cancer
|
2006
|
1.05
|
|
18
|
Self-assembled nanoparticles based on glycol chitosan bearing 5beta-cholanic acid for RGD peptide delivery.
|
J Control Release
|
2004
|
1.05
|
|
19
|
Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly(beta-amino ester) block copolymer micelles for cancer therapy.
|
J Control Release
|
2007
|
1.03
|
|
20
|
Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel.
|
J Control Release
|
2006
|
1.03
|
|
21
|
Tumoral acidic pH-responsive MPEG-poly(beta-amino ester) polymeric micelles for cancer targeting therapy.
|
J Control Release
|
2010
|
1.01
|
|
22
|
Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition.
|
Mol Cancer Ther
|
2006
|
1.01
|
|
23
|
Expression of TGF-beta-induced matrix protein betaig-h3 is up-regulated in the diabetic rat kidney and human proximal tubular epithelial cells treated with high glucose.
|
Kidney Int
|
2003
|
1.00
|
|
24
|
Regulation of tumor angiogenesis by fastatin, the fourth FAS1 domain of betaig-h3, via alphavbeta3 integrin.
|
Cancer Res
|
2005
|
0.99
|
|
25
|
Polymorphisms in the FAS and FASL genes and risk of lung cancer in a Korean population.
|
Lung Cancer
|
2006
|
0.95
|
|
26
|
Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity.
|
J Control Release
|
2006
|
0.94
|
|
27
|
Methyl-CpG binding domain 1 gene polymorphisms and risk of primary lung cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
0.90
|
|
28
|
In vivo imaging of tumor apoptosis using histone H1-targeting peptide.
|
J Control Release
|
2010
|
0.89
|
|
29
|
MEGF10 functions as a receptor for the uptake of amyloid-β.
|
FEBS Lett
|
2010
|
0.88
|
|
30
|
Polymorphisms in apoptosis-related genes and survival of patients with early-stage non-small-cell lung cancer.
|
Ann Surg Oncol
|
2010
|
0.88
|
|
31
|
Protein-phosphorylation-responsive polymeric nanoparticles for imaging protein kinase activities in single living cells.
|
Angew Chem Int Ed Engl
|
2007
|
0.88
|
|
32
|
Antitumor effect of a transducible fusogenic peptide releasing multiple proapoptotic peptides by caspase-3.
|
Mol Cancer Ther
|
2008
|
0.88
|
|
33
|
Differential gene expression analysis using paraffin-embedded tissues after laser microdissection.
|
J Cell Biochem
|
2003
|
0.87
|
|
34
|
pH- and temperature-sensitive, injectable, biodegradable block copolymer hydrogels as carriers for paclitaxel.
|
Int J Pharm
|
2006
|
0.86
|
|
35
|
Stimulation of fibroblasts and neuroblasts on a biomimetic extracellular matrix consisting of tandem repeats of the elastic VGVPG domain and RGD motif.
|
J Biomed Mater Res A
|
2011
|
0.86
|
|
36
|
Tumor endothelial cell targeted cyclic RGD-modified heparin derivative: inhibition of angiogenesis and tumor growth.
|
Pharm Res
|
2008
|
0.85
|
|
37
|
Antimetastatic effect of an orally active heparin derivative on experimentally induced metastasis.
|
Clin Cancer Res
|
2008
|
0.85
|
|
38
|
FAS1 domain protein inhibits VEGF165-induced angiogenesis by targeting the interaction between VEGFR-2 and αvβ3 integrin.
|
Mol Cancer Res
|
2012
|
0.84
|
|
39
|
Facilitated intracellular delivery of peptide-guided nanoparticles in tumor tissues.
|
J Control Release
|
2011
|
0.84
|
|
40
|
Identification of polymorphisms in the XIAP gene and analysis of association with lung cancer risk in a Korean population.
|
Cancer Genet Cytogenet
|
2008
|
0.82
|
|
41
|
Gas-generating polymeric microspheres for long-term and continuous in vivo ultrasound imaging.
|
Biomaterials
|
2011
|
0.81
|
|
42
|
The attenuation of experimental lung metastasis by a bile acid acylated-heparin derivative.
|
Biomaterials
|
2007
|
0.80
|
|
43
|
Construction and application of elastin like polypeptide containing IL-4 receptor targeting peptide.
|
PLoS One
|
2013
|
0.80
|
|
44
|
Antiangiogenic effect of bile acid acylated heparin derivative.
|
Pharm Res
|
2006
|
0.79
|
|
45
|
Gene expression profile of human chondrocyte HCS-2/8 cell line by EST sequencing analysis.
|
Gene
|
2004
|
0.79
|
|
46
|
Polymeric nanoparticles for protein kinase activity.
|
Chem Commun (Camb)
|
2007
|
0.78
|
|
47
|
Potentiation of anti-angiogenic activity of heparin by blocking the ATIII-interacting pentasaccharide unit and increasing net anionic charge.
|
Biomaterials
|
2012
|
0.77
|
|
48
|
An apoptosis-homing peptide-conjugated low molecular weight heparin-taurocholate conjugate with antitumor properties.
|
Biomaterials
|
2012
|
0.77
|
|
49
|
Combination therapy of heparin-deoxycholic acid conjugate and doxorubicin against squamous cell carcinoma and B16F10 melanoma.
|
Pharm Res
|
2007
|
0.76
|
|
50
|
T-CAM, a fastatin-FIII 9-10 fusion protein, potently enhances anti-angiogenic and anti-tumor activity via alphavbeta3 and alpha5beta1 integrins.
|
Exp Mol Med
|
2008
|
0.75
|